A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Hoffmann-La Roche207 enrolled

Overview

This study is designed to identify biomarkers which may predict improvement in progression free survival from treatment with Tarceva, in patients with advanced pancreatic cancer who failed one prior regimen of standard chemotherapy or who are deemed unsuitable for chemotherapy. It will also assess the efficacy and safety of Tarceva in this patient population. Patients will be randomized to receive either Tarceva 150mg/day po, or placebo po daily. Tumor tissue will be used for biomarker analysis. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

207

Conditions

Pancreatic Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients, \>=18 years of age; * histologically or cytologically documented locally advanced-unresectable or metastatic pancreatic cancer; * measurable disease according to RECIST; * failure of at least one prior chemotherapy regimen, or who are deemed unsuitable for chemotherapy; * ECOG performance status of 0-2. Exclusion Criteria: * local or locally advanced-resectable pancreatic cancer; * any other malignancies within last 5 years, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer; * major surgery within 2 weeks prior to randomization.

Locations (71)

Unnamed facility

Kogarah, New South Wales, Australia

Unnamed facility

St Leonards, New South Wales, Australia

Unnamed facility

Sydney, New South Wales, Australia

Unnamed facility

Box Hill, Victoria, Australia

Unnamed facility

Salvador, Bahia, Estado de Bahia, Brazil

Unnamed facility

Outcomes

Primary Outcomes

Progression-Free Survival

Progression-free survival (PFS) was defined as the time from the date of randomization to the date of the first occurrence of PD or death whichever occurred first. Participants without event were censored at the date of last tumor assessment where non-progression was documented. Analysis was performed using Kaplan-Meier method.

Time frame: From the time of randomization until progression of disease or death (up to 30 months)

Secondary Outcomes

Percentage of Participants With Best Overall Response Rate

Response rate was defined as Complete Response (CR) or Partial Response (PR), according to response evaluation criteria in solid tumors (RECIST) Version 1.0 criteria, for at least 4 weeks at any time during randomized treatment (confirmed response). CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.

Time frame: From the time of randomization until progression of disease or death (up to 30 months)

Percentage of Participants With Disease Control Rate (DCR)

Disease control rates (DCR) were measured according to RECIST Version 1.0 criteria. Disease control was defined as being a responder or as having stable disease for at least 6 weeks post-randomization. Stable disease was defined as having neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Time frame: Randomization to Clinical Cutoff: 20 December 2010 (up to 30 months)

Overall Survival

Overall survival was defined as the time from the date of randomization to the date of death, regardless of the cause of death.

Time frame: From the time of randomization until or death (up to 30 months)

Number of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who was administered a study treatment, regardless of whether or not the event had a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.

Time frame: Up to 28 days after discontinuation of study drug (up to 30 months)